{
  "name" : "dacemirror.sci-hub.se_journal-article_4cafce40634d5d8632cf728155973585_hosseini2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression",
    "authors" : [ "sare hosseini", "Jamshidkhan Chamani", "Mohammad reza hadipanah", "negar ebadpour", "amir sajjad hojjati", "Mohammad hasan Mohammadzadeh", "hamid reza rahimi" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "© 2019 Hosseini et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work\nyou hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).\nBreast Cancer - Targets and Therapy 2019:11 137–142"
    }, {
      "heading" : "Breast Cancer - Targets and Therapy Dovepress",
      "text" : "submit your manuscript | www.dovepress.com Dovepress 137\nO r i g i n a l r e s e a r C h\nopen access to scientific and medical research\nOpen Access Full Text Article\nhttp://dx.doi.org/10.2147/BCTT.S195800\nnano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression\nsare hosseini1 Jamshidkhan Chamani2 Mohammad reza hadipanah3 negar ebadpour4 amir sajjad hojjati4 Mohammad hasan Mohammadzadeh2 hamid reza rahimi5,6\n1Cancer research Center, Mashhad University of Medical sciences, Mashhad, iran; 2Department of Biology, Faculty of sciences, islamic azad University, Mashhad Branch, Mashhad, iran; 3student research Committee, Faculty of Medicine, Mashhad University of Medical sciences, Mashhad, iran; 4Department of laboratory sciences, school of Paramedical sciences, Mashhad University of Medical sciences, Mashhad, iran; 5neurogenic inflammation research Center, Mashhad University of Medical sciences, Mashhad, iran; 6Department of Modern sciences and Technologies, Faculty of Medicine, Mashhad University of Medical sciences, Mashhad, iran\nBackground: Breast cancer is the leading cause of cancer worldwide. The high expenses associated with chemotherapy as well as its side effects make the management of breast cancer\na daunting challenge. The most common overexpressed gene in breast cancer is cyclinD1, which\ninduces cell proliferation. Recent investigations into cancer treatment have revealed that curcumin\ndemonstrates potential anti-cancer properties through different pathways. However, the oral\nbioavailability of curcumin is negligible due to its high hydrophobic structure. Nanotechnology has been employed to overcome this barrier. Nano-formulated curcumin (SinaCurcumin®) has\nbeen shown to provide a significantly higher bioavailability for oral consumption. However, the\nefficacy of this nano-formulated drug in breast cancer has not yet been determined. In relation\nto the breast cancer cell line, the present study compared nano-curcumin’s anti-cancer properties\nwith those of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF). Methods: After treating MCF7 with nano-curcumin and CAF, the present work assessed cell viability via an MTT assay. The effects of these drugs on cyclinD1 expression were measured\nby real-time PCR. SPSS 16.0 was used to perform ANOVA and multiple range tests. Results: Nano-curcumin and the CAF regimen both lowered the viability of MCF7. Nanocurcumin decreased cell proliferation by 83.6%, which was more than that achieved by\ncyclophosphamide (63.31%), adriamycin (70.75%), and 5-fluorouracil (75.04%). In addition,\ncurcumin was able to significantly reduce the expression of cyclinD1, whereas CAF did not\nalter cyclinD1 expression. Conclusion: Nano-curcumin has a relatively high cytotoxic effect on MCF7 breast cancer cells, suppressing the expression of cyclinD1, a critical gene in the development and metastasis of\nbreast cancer. The current study demonstrated that nano-curcumin can be an effective drug in\nthe CAF regimen for the treatment of breast cancer. However, further in vivo research is needed\nfor determining its efficacy and safety in clinical applications. Keywords: nano-curcumin, cyclinD1, MCF7, patient survival, viability"
    }, {
      "heading" : "Introduction",
      "text" : "As a result of modern lifestyle-related risk factors, the incidence of breast cancer is rapidly growing worldwide .1–3 In Iran, studies have shown that the prevalence and mortality rate of breast cancer has risen as life expectancy has increased.4\nOne of the main etiologies of breast cancer is cyclin D overexpression, which causes\ncells to initiate the G1 phase of the cell cycle and activate the proliferation of signaling pathways .5,6 Studies have reported an association between cyclinD1 overexpression\nand tumor growth. The overexpression of cyclinD1 induces tumor formation through the ErbB2 protein and RAS oncogene .7 In addition, cyclinD1 promotes cell migration Correspondence: hamid reza rahimi Neurogenic Inflammation Research Center, Mashhad University of Medical sciences, Chancellery Building, PO Box: 91735-951, Mashhad, iran Tel +98 51 3800 2301 Fax +98 51 3800 2287 email rahimihr@mums.ac.ir\nJournal name: Breast Cancer - Targets and Therapy Article Designation: Original Research Year: 2019 Volume: 11 Running head verso: Hosseini et al Running head recto: Hosseini et al DOI: http://dx.doi.org/10.2147/BCTT.S195800\nB\nre as\nt C an\nce r:\nT ar\nge ts\na nd\nT he\nra py\nd ow\nnl oa\nde d\nfr om\nh ttp\ns: //w\nw w\n.d ov\nep re\nss .c\nom / b\ny 84\n.5 4.\n58 .2\n49 o\nn 05\n-A pr\n-2 01 9 F or p er so na l u se o nl y.\nPowered by TCPDF (www.tcpdf.org)\n1 / 1\nBreast Cancer - Targets and Therapy 2019:11submit your manuscript | www.dovepress.com Dovepress\nDovepress\n138\nhosseini et al\nand metastasis by inhibiting RhoGTPase and upregulating Rock2 and TSP-1.7 CyclinD1 through the phosphorylation of paxillin also increases tumor invasion .8 Taken together,\ncyclinD1 is associated with patient survival and prognosis.\nBreast cancer is treated by different methods, including surgery, chemotherapy, radiotherapy, and endocrine therapies.9–11 One of the most common treatments is chemotherapy.12\nVarious chemotherapeutic agents are employed to achieve\ntherapeutic goals, such as 5-fluorouracil, cyclophosphamide,\nand adriamycin. However, a universal standard regimen has\nnot yet been developed. The maximum tolerated dose of\nthese agents may be difficult to administer and often cause intensive side effects, including anemia,13,14 neutropenia,15 leukopenia,13 vomiting,16 liver toxicity, and hemorrhagic cystitis .13 Thus, there is a need for more effective methods to\nimprove upon the limitations of current treatments. The usage\nof natural compounds, in combination with common phar-\nmaceutical agents, has proven to be less cytotoxic and more effective .17 Many studies have demonstrated the potential\nuse of curcumin as a natural substance in combination with other routine treatments .18 Curcumin is a yellow substance\nthat is extracted from Curcuma longa. It is widely used as herbal supplement and food coloring agent in Asia.19\nThe anti-microbial,20–23 anti-inflammatory,24–26 and anticancer properties of curcumin27–30 have been mentioned in\nrecent works. The present study investigates the potential use of SinaCurcumin® for oral use which has been developed in\nNanotechnology Research Center of Mashhad University\nof Medical Science and marketed by Exir Nano Sina Com-\npany in Tehran, Iran (IRC:1228225765) and nano-micelle\ncurcumin for breast cancer treatment and their interaction\nwith the cyclinD1 pathway."
    }, {
      "heading" : "Materials and methods",
      "text" : ""
    }, {
      "heading" : "Drugs",
      "text" : "Nano-micelle curcumin was obtained from Exir Nano Sina\n(Iran). Each soft gel contains 80 mg of curcumin in the\nform of a nano-micelle. The current research also purchased\ncyclophosphamide (Baxter, Frankfurt, Germany), adriamy-\ncin (Ebewe, Unterach, Austria), and 5-fluorouracil (Biosyn,\nFellbach, Germany) for comparative studies."
    }, {
      "heading" : "Cell line",
      "text" : "Human breast cancer cells (MCF-7; ATCC® HTB-22TM,\nCat No: 85072011, NCBI NO: C135; ATCC, Manassas,\nVA, USA) were purchased from the cell bank at the Pasteur\nInstitute (Tehran, Iran) due to the presence of estrogen and\nprogesterone receptors. The present work prepared all the\nreagents and mediums immediately before application."
    }, {
      "heading" : "Cell culture",
      "text" : "MCF-7 cells were cultured in DMEM (Thermo Fisher Scien-\ntific, Waltham, MA, USA) and contained 10% FBS (Thermo\nFisher Scientific), penicillin (1% v/v), and streptomycin (1%\nv/v). The cells were incubated in 5% CO 2 at 37°C."
    }, {
      "heading" : "MTT assay",
      "text" : "The effects of nano-micelle curcumin, cyclophosphamide,\nadriamycin, and 5-fluorouracil on the viability of MCF-7 cells\nwere assessed by MTT assay (Sigma-Aldrich Co., St Louis,\nMO, USA). The cells were briefly seeded into a 96-well culture\nplate containing 100 µL of growth medium at 5,000 cells/well\nand then were incubated for 48 hours at 37°C in 5% CO 2 . Cells were treated with different drug concentrations: nano-micelle\ncurcumin: 0.62, 1.24, 2.52, 5.07, 10.17, 20.35, 40.71, 81.43,\nand 162.87 mmol/L; cyclophosphamide: 11.95, 23.93, 47.87,\n95.75, 191.5, 383.01, and 766.03 mmol/L; adriamycin: 0.28,\n0.57, 1.14, 2.29, 4.59, 9.19, and 18.39 mmol/L; and 5-fluo-\nrouracil: 29.98, 59.96, 81.49, 239.85, 480.48, 960.96, and\n1,921.93 mmol/L. After that, the cells were incubated for a\nsecond time for 24 hours in 5% CO 2 at 37°C. The old medium was replaced with 20 µL of MTT solution (0.5 mg/mL). The\nplates were incubated for 3.5 hours at 37°C. Afterward, forma-\nzan precipitate was dissolved in 200 µL of dimethyl sulfoxide\nand then added to the wells. An ELISA reader eventually\nquantified the absorption of the solution (Anthos, Carlton, VIC,\nAustralia) at 490 nm. As the percentage of cell viability, MTT assay results were expressed as mean ± SD. The half-maximal inhibitory concentrations (IC50) were measured as mg/mL.\nrna extraction To evaluate the gene expression, we loaded samples with\nnano-curcumin and drugs at IC50. An RNA extraction kit\n(Cat No: 11828665001; Hoffman-La Roche Ltd., Basel,\nSwitzerland) isolated the RNAs from the breast cancer cell\nline. Four samples were prepared according to the following instructions: MCF7 + nano-curcumin (A); MCF7 + cyclophosphamide + adriamycin + 5-fluorouracil (B); MCF7 + nano-curcumin (first 24 hours) + CAF (the second 24 hours) (C); and group D which included MCF7 as negative control.\nAn RNase/DNase-free environment was provided to carry out\nall the procedures. The present study determined the quality\nand quantity of the extracted RNA by gel electrophoresis and NanoDrop® (Thermo Fisher Scientific), respectively.\ncDna synthesis and real-time polymerase chain reaction A cDNA kit (Parstous, Tehran, Iran) reverse transcribed 10\nng of RNA according to the company’s instructions. Table 1\nB\nre as\nt C an\nce r:\nT ar\nge ts\na nd\nT he\nra py\nd ow\nnl oa\nde d\nfr om\nh ttp\ns: //w\nw w\n.d ov\nep re\nss .c\nom / b\ny 84\n.5 4.\n58 .2\n49 o\nn 05\n-A pr\n-2 01 9 F or p er so na l u se o nl y.\nPowered by TCPDF (www.tcpdf.org)\n1 / 1\nBreast Cancer - Targets and Therapy 2019:11 submit your manuscript | www.dovepress.com Dovepress\nDovepress\n139\nhosseini et al\npresents the sequence of primers employed for real-time PCR.\nTen micrograms of SYBR green PCR master mix (Parstous),\n1 µg of cDNA, and 10 µg of primer were mixed to prepare a reaction mixture. The 2−ΔΔCt method quantified the relative\ngene expression. For a reference gene, the results were nor-\nmalized to GAPDH. The following formula calculated fold change and ΔΔCt:\nFold change =2−ΔΔCt\nΔΔCt = Sample (Ct Target gene – Ct GAPDH ) – Reference sample (Ct\nTarget gene – Ct GAPDH )\nstatistical analysis The results were expressed as the mean ± SD. Following normal distribution, one-way ANOVA, and Tukey’s multiple\nrange tests were applied to calculate the significant difference. P-values <0.05 were considered to be statistically significant. All the tests were performed with SPSS 16.0 (SPSS Inc.,\nChicago, IL, USA)."
    }, {
      "heading" : "Results",
      "text" : ""
    }, {
      "heading" : "The results of the MTT test",
      "text" : "The MTT test showed that the highest rate of viability was\nobserved at a concentration of 0.62 mmol/L of curcumin. At\na curcumin concentration of 162.87 mmol/L, cell viability\nTable 1 Primers used in the current study\nPrimers Forward Backward\nCyclin D1 TgCaCCaCCaaCTgCTTagC ggCaTggaCTgTggTCaTgag gaPDh ggaTgCTggaggTCTgCgaggaaC gagaggaagCgTgTgaggCggTag\nreduced to 16%. In other words, increase in the concentra-\ntion of nano-micelle curcumin causes a gradual decrease in\ncell viability. This also occurred with other drugs. However,\ncurcumin reduced cell proliferation by 83.6%, which was\nmore than by cyclophosphamide (63.31%), adriamycin\n(70.75%), and 5-fluorouracil (75.04%). IC50 values were\nmeasured at 615.02, 170.97, 0.91, and 59.72 mmol/L with\nincreasing concentrations of 5-fluorouracil, cyclophospha-\nmide, adriamycin, and nano-curcumin, respectively. Figure 1\npresents the viability of cells after treatment.\nresults of melting curves obtained from"
    }, {
      "heading" : "PCr products",
      "text" : "CyclinD1 expression was significantly (P<0/005) lowered following the treatment with nano-curcumin (Sample A).\nThe gene expression ratio was calculated as 0.715 for sample\nA, 3.771 for CAF treatment (Sample B), and 1.431 for the\ncombination treatment (Sample C) as shown in Figure 2.\nConsidering Samples A and C, nano-curcumin represented\na significant inhibitory potential for cyclinD1 expression."
    }, {
      "heading" : "Discussion",
      "text" : "The leading cause of cancer is breast cancer, which holds fifth place in cancer-related deaths globally.31 The high cost\nof chemotherapy for treating breast cancer and its side effects\nFigure 1 The percentage of viability of breast cancer cells (MCF7) after treatment with four compounds . Note: Cytotoxicity of 5-fluorouracil, adriamycin, nano-curcumin, and cyclophosphamide.\n0.00 10.00 20.00 30.00 40.00 50.00 60.00 70.00 80.00 90.00\n100.00\n0 0.5 1 1.5 2 2.5 3\nVi ab\nili ty\n(% )\nLog concentration (mmol/L)\nCyclophosphamide Adriamycin 5-Fluorouracil Nano-curcumin\nB\nre as\nt C an\nce r:\nT ar\nge ts\na nd\nT he\nra py\nd ow\nnl oa\nde d\nfr om\nh ttp\ns: //w\nw w\n.d ov\nep re\nss .c\nom / b\ny 84\n.5 4.\n58 .2\n49 o\nn 05\n-A pr\n-2 01 9 F or p er so na l u se o nl y.\nPowered by TCPDF (www.tcpdf.org)\n1 / 1\nBreast Cancer - Targets and Therapy 2019:11submit your manuscript | www.dovepress.com Dovepress\nDovepress\n140\nhosseini et al\nmake this disease one of the most challenging.32 The most common gene over expressed in breast cancer is cyclinD1.33\nRecent research on cancer treatment has reported that cur-\ncumin demonstrates potential anti-cancer properties via different pathways .34\nOne of the main targets inhibited by curcumin is NF-ĸB, which plays a vital role in oncogenic transformation.35\nHowever, the oral bioavailability of curcumin is negligible\ndue to its strong hydrophobic structure. Nanotechnology has\nbeen employed to overcome this barrier. Nano-formulated curcumin (SinaCurcumin®) has been demonstrated to provide\nsignificantly higher bioavailability by oral consumption. Fol-\nlowing the improvement of bioavailability of curcumin, its inhibitory effects can improve.19\nThe current study investigated the effects of nano-curcumin\non the MCF7 cell line. The results indicated that nano-cur-\ncumin decreased cell proliferation by 83.6%, which was more\nthan that achieved by cyclophosphamide (63.31%), adriamycin\n(70.75%), and 5-fluorouracil (75.04%). This demonstrates\nthat nano-curcumin has more potential to inhibit MCF7 cell\nproliferation in comparison to CAF. CyclinD1 expression\nwas significantly downregulated following treatment with\ncurcumin, whereas CAF demonstrated no notable inhibition of\ncyclinD1 expression. Liu et al revealed that curcumin inhibits MCF7 cells by suppressing the NF-κB signaling pathway.35 This suppression was induced by the inhibition of ubiquitin\nproteasome system (UPS) via curcumin. Inactivation of UPS inhibits dissociation of ikBα from NF-κB; so NF-κB cannot enter the nucleus and cyclinD1 expression will be blocked.36,37 Altogether, NF-κB signaling pathway suppression downregulates cyclinD1 expression and decreases MCF7 proliferation.38\nThe other mechanism describing the underlying pathway\nof inhibition of MCF7 proliferation is through Bcl-2. It has\nbeen reported that curcumin decreases Bcl-2 in breast cancer\ncells. As a result, the increase in the BAX/Bcl2 ratio leads to curcumin-induced apoptosis in cancer cells.39 In addition,\nincrease in P53, a tumor suppressor protein, expression lead\nto BAX expression after curcumin treatment in MCF7 cells. This also causes the apoptosis in cancer cells.40 The anti-cancer\neffects of curcumin on other breast cancer cell lines (MDAMB231 and JIMT1) have been also reported.39,41\nConfirming the present work’s results, Hajigholami et al\nreported that nano-packaged tamoxifen and curcumin not\nonly increased the anti-cancer properties of MCF7, but these also lowered the toxicity of normal cells .42 Unfortunately,\nthe current study did not assay the curcumin toxicity toward\nnormal cells. Also, we could not assess the protein levels of\ncyclinD1 and marker of apoptosis due to the financial limita-\ntion. Altogether, nano-curcumin offers an effective and safe\nmethod to treat breast cancer cells in vitro. On the other hand,\ncompared to CAF, curcumin weakened cyclinD1 expression to a significant extent.43"
    }, {
      "heading" : "Conclusion",
      "text" : "Curcumin may inhibit tumor proliferation, and also increase\npatient survival by inhibiting metastasis and changing in the\nexpression of cyclinD1. This has made curcumin a potential\nanti-cancer agent. However, further in vivo investigation is\nneeded to assess curcumin’s efficacy and safety in clinical\napplications."
    }, {
      "heading" : "Acknowledgment",
      "text" : "Mashhad University of Medical Sciences approved this study\nand had no role in the design and conduct of the study.\nFigure 2 expression of cyclinD1 in different samples compared to gaPDh.\n1 0.715730112\n1.43146022\n3.77106076\n0\n0.5\n1\n1.5\n2\n2.5\n3\n3.5\n4\n4.5\nControl Curcumin Combination Drug\n2– ∆∆ C t\nB\nre as\nt C an\nce r:\nT ar\nge ts\na nd\nT he\nra py\nd ow\nnl oa\nde d\nfr om\nh ttp\ns: //w\nw w\n.d ov\nep re\nss .c\nom / b\ny 84\n.5 4.\n58 .2\n49 o\nn 05\n-A pr\n-2 01 9 F or p er so na l u se o nl y.\nPowered by TCPDF (www.tcpdf.org)\n1 / 1\nBreast Cancer - Targets and Therapy 2019:11 submit your manuscript | www.dovepress.com Dovepress\nDovepress\n141\nhosseini et al"
    }, {
      "heading" : "Disclosure",
      "text" : "The authors report no conflicts of interest in this work."
    } ],
    "references" : [ {
      "title" : "Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy",
      "author" : [ "MAO Mendonça", "FQ Cunha", "EF Murta", "BM. Tavares-Murta" ],
      "venue" : "Cancer Chemother Pharmacol",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2006
    }, {
      "title" : "Enhanced and selective antiproliferative activity of Methotrexate-Functionalized-Nanocapsules to human breast cancer cells (MCF-7)",
      "author" : [ "C de Oliveira", "S Büttenbender", "W Prado" ],
      "venue" : "Nanomaterials (Basel)",
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 2018
    }, {
      "title" : "Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance",
      "author" : [ "A Shapira", "YD Livney", "HJ Broxterman", "YG. Assaraf" ],
      "venue" : "Drug Resist Updat",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 2011
    }, {
      "title" : "The globalisation of breast cancer",
      "author" : [ "P Boyle", "A. Howell" ],
      "venue" : "Breast Cancer Res. 2010;12(Suppl 4):S7",
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 2010
    }, {
      "title" : "Temporal tracking of cell cycle progression using flow cytometry without the need for synchronization",
      "author" : [ "Welschinger R", "Bendall LJ" ],
      "venue" : "J Vis Exp",
      "citeRegEx" : "5",
      "shortCiteRegEx" : "5",
      "year" : 2015
    }, {
      "title" : "Cyclin D as a therapeutic target in cancer",
      "author" : [ "EA Musgrove", "CE Caldon", "J Barraclough", "A Stone", "RL. Sutherland" ],
      "venue" : "Nat Rev Cancer",
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2011
    }, {
      "title" : "Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present",
      "author" : [ "MC Casimiro", "M Velasco-Velázquez", "C Aguirre-Alvarado", "RG. Pestell" ],
      "venue" : "Expert Opin Investig Drugs",
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2014
    }, {
      "title" : "Cyclin D1 promotes tumor cell invasion and metastasis by cytoplasmic mechanisms",
      "author" : [ "NP Fusté", "F Ferrezuelo", "E. Garí" ],
      "venue" : "Mol Cell Oncol",
      "citeRegEx" : "8",
      "shortCiteRegEx" : "8",
      "year" : 2034
    }, {
      "title" : "Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer",
      "author" : [ "Howell A", "Cuzick J", "Baum M", "ATAC Trialists’ Group" ],
      "venue" : null,
      "citeRegEx" : "9",
      "shortCiteRegEx" : "9",
      "year" : 2005
    }, {
      "title" : "Reply to survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status",
      "author" : [ "ES Hwang", "CA Clarke", "SL. Gomez" ],
      "venue" : null,
      "citeRegEx" : "11",
      "shortCiteRegEx" : "11",
      "year" : 2013
    }, {
      "title" : "Combination Therapies in Advanced, Hormone ReceptorPositive Breast Cancer",
      "author" : [ "E. Olson" ],
      "venue" : "J Adv Pract Oncol",
      "citeRegEx" : "12",
      "shortCiteRegEx" : "12",
      "year" : 2018
    }, {
      "title" : "Efficacy and toxicity of metronomic chemotherapy in metastatic breast cancer: Egyptian experience",
      "author" : [ "MM Hussein", "RM Gaafar", "AM Abdel-Warith" ],
      "venue" : "Clin Breast Cancer",
      "citeRegEx" : "13",
      "shortCiteRegEx" : "13",
      "year" : 2017
    }, {
      "title" : "AIOM Lombardia. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey",
      "author" : [ "D Cortinovis", "G Beretta", "E Piazza" ],
      "venue" : "Tumori",
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2013
    }, {
      "title" : "Suboptimal duration of granulocyte colony-stimulating factor use and chemotherapy-induced neutropenia in women diagnosed with breast cancer",
      "author" : [ "WT Lin", "YW Wen", "CR Chien", "CS Gau", "SC Chiang", "FY. Hsiao" ],
      "venue" : "Clin Ther",
      "citeRegEx" : "15",
      "shortCiteRegEx" : "15",
      "year" : 2014
    }, {
      "title" : "Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer",
      "author" : [ "M Arslan", "L. Ozdemir" ],
      "venue" : "Clin J Oncol Nurs",
      "citeRegEx" : "16",
      "shortCiteRegEx" : "16",
      "year" : 2015
    }, {
      "title" : "The value of plants used in traditional medicine for drug discovery",
      "author" : [ "Fabricant DS", "Farnsworth NR" ],
      "venue" : "Environ Health Perspect",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 2001
    }, {
      "title" : "Curcumin and cancer: barriers to obtaining a health claim",
      "author" : [ "JG Devassy", "ID Nwachukwu", "PJ. Jones" ],
      "venue" : "Nutr Rev",
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 2015
    }, {
      "title" : "Novel delivery system for natural products: Nano-curcumin formulations",
      "author" : [ "HR Rahimi", "R Nedaeinia", "A Sepehri Shamloo", "S Nikdoust", "R. Kazemi Oskuee" ],
      "venue" : "Avicenna J Phytomed",
      "citeRegEx" : "19",
      "shortCiteRegEx" : "19",
      "year" : 2016
    }, {
      "title" : "Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice",
      "author" : [ "R De", "P Kundu", "S Swarnakar" ],
      "venue" : "Antimicrob Agents Chemother",
      "citeRegEx" : "20",
      "shortCiteRegEx" : "20",
      "year" : 2009
    }, {
      "title" : "Curcumin protects microglia and primary rat cortical neurons against HIV-1 gp120-mediated inflammation and apoptosis",
      "author" : [ "L Guo", "Y Xing", "R Pan" ],
      "venue" : "PLoS One",
      "citeRegEx" : "21",
      "shortCiteRegEx" : "21",
      "year" : 2013
    }, {
      "title" : "Antimicrobial activity of curcumin-loaded myristic acid microemulsions against Staphylococcus epidermidis",
      "author" : [ "Liu CH", "Huang HY" ],
      "venue" : "Chem Pharm Bull (Tokyo)",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2012
    }, {
      "title" : "Antibacterial and antiinflammatory kinetics of curcumin as a potential antimucositis agent in cancer patients",
      "author" : [ "S Lüer", "R Troller", "C. Aebi" ],
      "venue" : "Nutr Cancer",
      "citeRegEx" : "23",
      "shortCiteRegEx" : "23",
      "year" : 2012
    }, {
      "title" : "Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications",
      "author" : [ "B Meng", "J Li", "H. Cao" ],
      "venue" : "Curr Pharm Des",
      "citeRegEx" : "24",
      "shortCiteRegEx" : "24",
      "year" : 2013
    }, {
      "title" : "Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model",
      "author" : [ "Adapala N", "Chan MM" ],
      "venue" : "Lab Invest",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2008
    }, {
      "title" : "The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial",
      "author" : [ "HR Rahimi", "AH Mohammadpour", "M Dastani" ],
      "venue" : "Avicenna J Phytomed",
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2016
    }, {
      "title" : "A pilot study of the antioxidant effect of curcumin in tropical pancreatitis",
      "author" : [ "S Durgaprasad", "CG Pai", "Vasanthkumar", "JF Alvres", "S. Namitha" ],
      "venue" : "Indian J Med Res",
      "citeRegEx" : "27",
      "shortCiteRegEx" : "27",
      "year" : 2005
    }, {
      "title" : "Curcumin, a component of turmeric: from farm to pharmacy",
      "author" : [ "SC Gupta", "G Kismali", "BB. Aggarwal" ],
      "venue" : "Biofactors",
      "citeRegEx" : "28",
      "shortCiteRegEx" : "28",
      "year" : 2013
    }, {
      "title" : "Curcumin in chemoprevention of breast cancer",
      "author" : [ "K Terlikowska", "A Witkowska", "S. Terlikowski" ],
      "venue" : "Postępy Higieny i Medycyny Doświadczalnej",
      "citeRegEx" : "29",
      "shortCiteRegEx" : "29",
      "year" : 2014
    }, {
      "title" : "Targeting breast stem cells with the cancer preventive compounds curcumin and piperine",
      "author" : [ "M Kakarala", "DE Brenner", "H Korkaya" ],
      "venue" : "Breast Cancer Res Treat",
      "citeRegEx" : "30",
      "shortCiteRegEx" : "30",
      "year" : 2010
    }, {
      "title" : "Global Burden of Disease Cancer Collaboration. Global, regional, and National cancer incidence, mortality, years of life lost, years lived with disability, and DisabilityAdjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of Disease Study",
      "author" : [ "C Fitzmaurice", "C Allen", "RM Barber" ],
      "venue" : "JAMA Oncol",
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 2017
    }, {
      "title" : "Comparison of treatment costs for breast cancer, by tumor stage and type of service",
      "author" : [ "H Blumen", "K Fitch", "V. Polkus" ],
      "venue" : "Am Health Drug Benefits",
      "citeRegEx" : "32",
      "shortCiteRegEx" : "32",
      "year" : 2016
    }, {
      "title" : "Nuclear cyclin D1: An oncogenic driver in human cancer",
      "author" : [ "Kim JK", "Diehl JA" ],
      "venue" : "J Cell Physiol",
      "citeRegEx" : "33",
      "shortCiteRegEx" : "33",
      "year" : 2009
    }, {
      "title" : "Evaluation of cytotoxicity effects of combination Nano-Curcumin and berberine in breast cancer cell line",
      "author" : [ "P Ziasarabi", "a Hesari", "M Bagheri", "M Baazm", "F. Ghasemi" ],
      "venue" : "Iran J Toxicol",
      "citeRegEx" : "34",
      "shortCiteRegEx" : "34",
      "year" : 2018
    }, {
      "title" : "Curcumin inhibits MCF-7 cells by modulating the NF-κB signaling pathway",
      "author" : [ "JL Liu", "YY Pan", "O Chen" ],
      "venue" : "Oncol Lett",
      "citeRegEx" : "35",
      "shortCiteRegEx" : "35",
      "year" : 2017
    }, {
      "title" : "Natural antioxidants. III. antioxidative components isolated from rhizome of Curcuma longa L",
      "author" : [ "S Toda", "T Miyase", "H Arichi", "H Tanizawa", "Y. Takino" ],
      "venue" : null,
      "citeRegEx" : "36",
      "shortCiteRegEx" : "36",
      "year" : 1985
    }, {
      "title" : "Minireview: cyclin D1: normal and abnormal functions. Endocrinology",
      "author" : [ "M Fu", "C Wang", "Z Li", "T Sakamaki", "RG. Pestell" ],
      "venue" : null,
      "citeRegEx" : "37",
      "shortCiteRegEx" : "37",
      "year" : 2004
    }, {
      "title" : "Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis",
      "author" : [ "JH Kim", "SC Gupta", "B Park", "VR Yadav", "BB. Aggarwal" ],
      "venue" : "Mol Nutr Food Res",
      "citeRegEx" : "38",
      "shortCiteRegEx" : "38",
      "year" : 2012
    }, {
      "title" : "Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo",
      "author" : [ "ZD Lv", "XP Liu", "WJ Zhao" ],
      "venue" : "Int J Clin Exp Pathol",
      "citeRegEx" : "39",
      "shortCiteRegEx" : "39",
      "year" : 2014
    }, {
      "title" : "Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction",
      "author" : [ "T Choudhuri", "S Pal", "ML Agwarwal", "T Das", "G. Sa" ],
      "venue" : "FEBS Lett. 2002;512(1–3):334–340",
      "citeRegEx" : "40",
      "shortCiteRegEx" : "40",
      "year" : 2019
    }, {
      "title" : "Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells",
      "author" : [ "A Catania", "E Barrajón-Catalán", "S Nicolosi", "F Cicirata", "V. Micol" ],
      "venue" : "Breast Cancer Res Treat",
      "citeRegEx" : "41",
      "shortCiteRegEx" : "41",
      "year" : 2013
    }, {
      "title" : "Nano packaged tamoxifen and curcumin; effective formulation against sensitive and resistant MCF-7 cells",
      "author" : [ "S Hajigholami", "Z Veisi Malekshahi", "N Bodaghabadi", "F Najafi", "H Shirzad", "M. Sadeghizadeh" ],
      "venue" : "Iran J Pharm Res",
      "citeRegEx" : "42",
      "shortCiteRegEx" : "42",
      "year" : 2018
    }, {
      "title" : "An in vitro study on curcumin delivery by nano-micelles for esophageal squamous cell carcinoma",
      "author" : [ "S Hosseini", "J Chamani", "H Rahimi", "N Azmoodeh", "F Ghasemi", "PH. Abadi" ],
      "venue" : "Rep Biochem Mol Biol",
      "citeRegEx" : "43",
      "shortCiteRegEx" : "43",
      "year" : 2018
    } ],
    "referenceMentions" : [ {
      "referenceID" : 3,
      "context" : "In Iran, studies have shown that the prevalence and mortality rate of breast cancer has risen as life expectancy has increased.(4) One of the main etiologies of breast cancer is cyclin D overexpression, which causes cells to initiate the G1 phase of the cell cycle and activate the proliferation of signaling pathways .",
      "startOffset" : 127,
      "endOffset" : 130
    }, {
      "referenceID" : 4,
      "context" : "One of the main etiologies of breast cancer is cyclin D overexpression, which causes cells to initiate the G1 phase of the cell cycle and activate the proliferation of signaling pathways .(5,6) Studies have reported an association between cyclinD1 overexpression and tumor growth.",
      "startOffset" : 188,
      "endOffset" : 193
    }, {
      "referenceID" : 5,
      "context" : "One of the main etiologies of breast cancer is cyclin D overexpression, which causes cells to initiate the G1 phase of the cell cycle and activate the proliferation of signaling pathways .(5,6) Studies have reported an association between cyclinD1 overexpression and tumor growth.",
      "startOffset" : 188,
      "endOffset" : 193
    }, {
      "referenceID" : 6,
      "context" : "The overexpression of cyclinD1 induces tumor formation through the ErbB2 protein and RAS oncogene .(7) In addition, cyclinD1 promotes cell migration Correspondence: hamid reza rahimi Neurogenic Inflammation Research Center, Mashhad University of Medical sciences, Chancellery Building, PO Box: 91735-951, Mashhad, iran Tel +98 51 3800 2301 Fax +98 51 3800 2287 email rahimihr@mums.",
      "startOffset" : 99,
      "endOffset" : 102
    }, {
      "referenceID" : 6,
      "context" : "and metastasis by inhibiting RhoGTPase and upregulating Rock2 and TSP-1.(7) CyclinD1 through the phosphorylation of paxillin also increases tumor invasion .",
      "startOffset" : 72,
      "endOffset" : 75
    }, {
      "referenceID" : 7,
      "context" : "CyclinD1 through the phosphorylation of paxillin also increases tumor invasion .(8) Taken together, cyclinD1 is associated with patient survival and prognosis.",
      "startOffset" : 80,
      "endOffset" : 83
    }, {
      "referenceID" : 10,
      "context" : "One of the most common treatments is chemotherapy.(12) Various chemotherapeutic agents are employed to achieve therapeutic goals, such as 5-fluorouracil, cyclophosphamide, and adriamycin.",
      "startOffset" : 50,
      "endOffset" : 54
    }, {
      "referenceID" : 11,
      "context" : "The maximum tolerated dose of these agents may be difficult to administer and often cause intensive side effects, including anemia,(13,14) neutropenia,(15) leukopenia,(13) vomiting,(16) liver toxicity, and hemorrhagic cystitis .(13) Thus, there is a need for more effective methods to improve upon the limitations of current treatments.",
      "startOffset" : 228,
      "endOffset" : 232
    }, {
      "referenceID" : 15,
      "context" : "The usage of natural compounds, in combination with common pharmaceutical agents, has proven to be less cytotoxic and more effective .(17) Many studies have demonstrated the potential use of curcumin as a natural substance in combination with other routine treatments .",
      "startOffset" : 134,
      "endOffset" : 138
    }, {
      "referenceID" : 16,
      "context" : "Many studies have demonstrated the potential use of curcumin as a natural substance in combination with other routine treatments .(18) Curcumin is a yellow substance that is extracted from Curcuma longa.",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 17,
      "context" : "It is widely used as herbal supplement and food coloring agent in Asia.(19) The anti-microbial, anti-inflammatory, and anticancer properties of curcumin have been mentioned in recent works.",
      "startOffset" : 71,
      "endOffset" : 75
    }, {
      "referenceID" : 29,
      "context" : "Discussion The leading cause of cancer is breast cancer, which holds fifth place in cancer-related deaths globally.(31) The high cost of chemotherapy for treating breast cancer and its side effects",
      "startOffset" : 115,
      "endOffset" : 119
    }, {
      "referenceID" : 30,
      "context" : "make this disease one of the most challenging.(32) The most common gene over expressed in breast cancer is cyclinD1.",
      "startOffset" : 46,
      "endOffset" : 50
    }, {
      "referenceID" : 31,
      "context" : "The most common gene over expressed in breast cancer is cyclinD1.(33) Recent research on cancer treatment has reported that curcumin demonstrates potential anti-cancer properties via different pathways .",
      "startOffset" : 65,
      "endOffset" : 69
    }, {
      "referenceID" : 32,
      "context" : "Recent research on cancer treatment has reported that curcumin demonstrates potential anti-cancer properties via different pathways .(34) One of the main targets inhibited by curcumin is NF-ĸB, which plays a vital role in oncogenic transformation.",
      "startOffset" : 133,
      "endOffset" : 137
    }, {
      "referenceID" : 33,
      "context" : "One of the main targets inhibited by curcumin is NF-ĸB, which plays a vital role in oncogenic transformation.(35) However, the oral bioavailability of curcumin is negligible due to its strong hydrophobic structure.",
      "startOffset" : 109,
      "endOffset" : 113
    }, {
      "referenceID" : 17,
      "context" : "Following the improvement of bioavailability of curcumin, its inhibitory effects can improve.(19) The current study investigated the effects of nano-curcumin on the MCF7 cell line.",
      "startOffset" : 93,
      "endOffset" : 97
    }, {
      "referenceID" : 33,
      "context" : "Liu et al revealed that curcumin inhibits MCF7 cells by suppressing the NF-κB signaling pathway.(35) This suppression was induced by the inhibition of ubiquitin proteasome system (UPS) via curcumin.",
      "startOffset" : 96,
      "endOffset" : 100
    }, {
      "referenceID" : 34,
      "context" : "Inactivation of UPS inhibits dissociation of ikBα from NF-κB; so NF-κB cannot enter the nucleus and cyclinD1 expression will be blocked.(36,37) Altogether, NF-κB signaling pathway suppression downregulates cyclinD1 expression and decreases MCF7 proliferation.",
      "startOffset" : 136,
      "endOffset" : 143
    }, {
      "referenceID" : 35,
      "context" : "Inactivation of UPS inhibits dissociation of ikBα from NF-κB; so NF-κB cannot enter the nucleus and cyclinD1 expression will be blocked.(36,37) Altogether, NF-κB signaling pathway suppression downregulates cyclinD1 expression and decreases MCF7 proliferation.",
      "startOffset" : 136,
      "endOffset" : 143
    }, {
      "referenceID" : 36,
      "context" : "Altogether, NF-κB signaling pathway suppression downregulates cyclinD1 expression and decreases MCF7 proliferation.(38) The other mechanism describing the underlying pathway of inhibition of MCF7 proliferation is through Bcl-2.",
      "startOffset" : 115,
      "endOffset" : 119
    }, {
      "referenceID" : 37,
      "context" : "As a result, the increase in the BAX/Bcl2 ratio leads to curcumin-induced apoptosis in cancer cells.(39) In addition, increase in P53, a tumor suppressor protein, expression lead to BAX expression after curcumin treatment in MCF7 cells.",
      "startOffset" : 100,
      "endOffset" : 104
    }, {
      "referenceID" : 38,
      "context" : "This also causes the apoptosis in cancer cells.(40) The anti-cancer effects of curcumin on other breast cancer cell lines (MDAMB231 and JIMT1) have been also reported.",
      "startOffset" : 47,
      "endOffset" : 51
    }, {
      "referenceID" : 37,
      "context" : "The anti-cancer effects of curcumin on other breast cancer cell lines (MDAMB231 and JIMT1) have been also reported.(39,41) Confirming the present work’s results, Hajigholami et al reported that nano-packaged tamoxifen and curcumin not only increased the anti-cancer properties of MCF7, but these also lowered the toxicity of normal cells .",
      "startOffset" : 115,
      "endOffset" : 122
    }, {
      "referenceID" : 39,
      "context" : "The anti-cancer effects of curcumin on other breast cancer cell lines (MDAMB231 and JIMT1) have been also reported.(39,41) Confirming the present work’s results, Hajigholami et al reported that nano-packaged tamoxifen and curcumin not only increased the anti-cancer properties of MCF7, but these also lowered the toxicity of normal cells .",
      "startOffset" : 115,
      "endOffset" : 122
    }, {
      "referenceID" : 40,
      "context" : "Confirming the present work’s results, Hajigholami et al reported that nano-packaged tamoxifen and curcumin not only increased the anti-cancer properties of MCF7, but these also lowered the toxicity of normal cells .(42) Unfortunately, the current study did not assay the curcumin toxicity toward normal cells.",
      "startOffset" : 216,
      "endOffset" : 220
    }, {
      "referenceID" : 41,
      "context" : "On the other hand, compared to CAF, curcumin weakened cyclinD1 expression to a significant extent.(43)",
      "startOffset" : 98,
      "endOffset" : 102
    } ],
    "year" : 2019,
    "abstractText" : "php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Breast Cancer Targets and Therapy 2019:11 137–142 Breast Cancer Targets and Therapy Dovepress",
    "creator" : "Adobe InDesign CS6 (Windows)"
  }
}